Boehringer Ingelheim and the associated logos are trademarks of Boehringer Ingelheim International GmbH.

Boehringer Ingelheim is a global, research-driven pharmaceutical company with a strong commitment to innovation in cardiometabolic diseases. With a proven track record in diabetes, obesity, and cardiovascular care, Boehringer Ingelheim is expanding its pipeline to address metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH)—conditions that lie at the intersection of metabolic syndrome, inflammation, and organ fibrosis.

At the forefront of this expansion is the company’s investigational therapy survodutide, a novel GLP-1/glucagon receptor dual agonist developed in partnership with Zealand Pharma. Survodutide is designed to reduce hepatic steatosis, improve insulin sensitivity, promote weight loss, and address systemic inflammation—key drivers of MASH pathogenesis. Currently being evaluated in Phase 2 trials, survodutide has shown promising results in significantly reducing liver fat content and resolving MASH in patients with and without diabetes.

Boehringer Ingelheim is also advancing multi-targeted approaches for MASH, focusing on the interplay between liver, heart, and kidney health. Its pipeline includes agents aimed at fibrotic remodeling, metabolic correction, and immune modulation, reflecting the company’s integrated view of disease progression and comorbidity management.

With a strong foundation in cardiometabolic care and a vision for precision liver medicine, Boehringer Ingelheim is poised to play a leading role in the evolving therapeutic landscape of MASH. Through a combination of cutting-edge science, strategic partnerships, and patient-centered innovation, the company aims to deliver transformative solutions for those living with advanced liver disease.